Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis

• Published in: Cancer research (Chicago, Ill.) Vol. 57; no. 9; pp. 1634 - 1637
• Main Authors: GANSAUGE, S, GANSAUGE, F, RAMADANI, M, STOBBE, H, RAU, B, HARADA, N, BEGER, H. G
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.05.1997
• Subjects: Adult; Aged; Biological and medical sciences; Carcinoma - diagnosis; Carcinoma - genetics; Cyclin D1; Cyclins - genetics; Cyclins - metabolism; Female; Gastroenterology. Liver. Pancreas. Abdomen; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Middle Aged; Oncogene Proteins - genetics; Oncogene Proteins - metabolism; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - genetics; Prognosis; RNA, Messenger - genetics; RNA, Neoplasm - genetics; Survival Analysis; Tumors; Adenocarcinoma; Human; Prognosis; Cyclin; Gene overexpression; Malignant tumor; Gene expression; Cyclin D1; Tissue; Digestive diseases; Pancreas; Nuclear protein; Pancreatic disease
• ISSN: 0008-5472; 1538-7445

We have investigated the expression of cyclin D1 in adenocarcinoma of the pancreas and the relevance of cyclin D1 expression to clinical outcome. In comparison to normal pancreas, Southern blot analyses revealed amplification of the cyclin D1 coding gene in 25% of the cases, whereas with reverse transcription-PCR, overexpression of mRNA was observed in 82% of the examined tissues. Immunohistochemically, we could demonstrate nuclear overexpression in tumor cells in 68.4%, and this protein accumulation correlated significantly with poor prognosis [median survival, 18.1 versus 10.5 months; P < 0.01 (chi2 test)].